Alpha 2.0

» Articles » PMID: 34477226

Forty-fifth ASPEN Presidential Address: Research in a Pandemic-Why, What, How?

Overview

Overview

Journal JPEN J Parenter Enteral Nutr

Publisher Wiley

Specialty Nutritional Sciences

Date 2021 Sep 3

PMID 34477226

Citations 1

Authors

Authors

Todd W Rice

Affiliations

Affiliations

Soon will be listed here.

Citing Articles

Forty-fifth ASPEN Presidential Address: Research in a pandemic-Why, what, how?.

Rice T JPEN J Parenter Enteral Nutr. 2021; 45(8):1690-1702.

PMID: 34477226 PMC: 8646289. DOI: 10.1002/jpen.2261.

References

1.

Rice T . Forty-fifth ASPEN Presidential Address: Research in a pandemic-Why, what, how?. JPEN J Parenter Enteral Nutr. 2021; 45(8):1690-1702. PMC: 8646289. DOI: 10.1002/jpen.2261. View

2.

Mikulska M, Nicolini L, Signori A, Di Biagio A, Sepulcri C, Russo C . Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. PLoS One. 2020; 15(8):e0237831. PMC: 7440633. DOI: 10.1371/journal.pone.0237831. View

3.

Rice T, Janz D . In Defense of Evidence-based Medicine for the Treatment of COVID-19 Acute Respiratory Distress Syndrome. Ann Am Thorac Soc. 2020; 17(7):787-789. PMC: 7328187. DOI: 10.1513/AnnalsATS.202004-325IP. View

4.

Slaoui M, Hepburn M . Developing Safe and Effective Covid Vaccines - Operation Warp Speed's Strategy and Approach. N Engl J Med. 2020; 383(18):1701-1703. DOI: 10.1056/NEJMp2027405. View

5.

Lindsell C, Gatto C, Dear M, Buie R, Rice T, Pulley J . Learning From What We Do, and Doing What We Learn: A Learning Health Care System in Action. Acad Med. 2021; 96(9):1291-1299. DOI: 10.1097/ACM.0000000000004021. View

6.

Beigel J, Tomashek K, Dodd L, Mehta A, Zingman B, Kalil A . Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020; 383(19):1813-1826. PMC: 7262788. DOI: 10.1056/NEJMoa2007764. View

7.

Solaimanzadeh I . Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19). Cureus. 2020; 12(3):e7343. PMC: 7096066. DOI: 10.7759/cureus.7343. View

8.

Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D . COVID-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2020; 201(10):1299-1300. PMC: 7233352. DOI: 10.1164/rccm.202003-0817LE. View

9.

Gordon A, Mouncey P, Al-Beidh F, Rowan K, Nichol A, Arabi Y . Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021; 384(16):1491-1502. PMC: 7953461. DOI: 10.1056/NEJMoa2100433. View

10.

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

11.

Lenze E, Mattar C, Zorumski C, Stevens A, Schweiger J, Nicol G . Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(22):2292-2300. PMC: 7662481. DOI: 10.1001/jama.2020.22760. View

12.

Pan H, Peto R, Henao-Restrepo A, Preziosi M, Sathiyamoorthy V, Abdool Karim Q . Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2020; 384(6):497-511. PMC: 7727327. DOI: 10.1056/NEJMoa2023184. View

13.

Korley F, Durkalski-Mauldin V, Yeatts S, Schulman K, Davenport R, Dumont L . Early Convalescent Plasma for High-Risk Outpatients with Covid-19. N Engl J Med. 2021; 385(21):1951-1960. PMC: 8385553. DOI: 10.1056/NEJMoa2103784. View

14.

Self W, Semler M, Leither L, Casey J, Angus D, Brower R . Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(21):2165-2176. PMC: 7653542. DOI: 10.1001/jama.2020.22240. View

15.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

16.

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P . In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 71(15):732-739. PMC: 7108130. DOI: 10.1093/cid/ciaa237. View

17.

Acharya Y, Sayed A . Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review. Ther Adv Infect Dis. 2020; 7:2049936120947517. PMC: 7404096. DOI: 10.1177/2049936120947517. View

18.

Fan E, Beitler J, Brochard L, Calfee C, Ferguson N, Slutsky A . COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?. Lancet Respir Med. 2020; 8(8):816-821. PMC: 7338016. DOI: 10.1016/S2213-2600(20)30304-0. View

19.

Heyland D, Patel J, Bear D, Sacks G, Nixdorf H, Dolan J . The Effect of Higher Protein Dosing in Critically Ill Patients: A Multicenter Registry-Based Randomized Trial: The EFFORT Trial. JPEN J Parenter Enteral Nutr. 2018; 43(3):326-334. DOI: 10.1002/jpen.1449. View

20.

Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H . Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020; 6:16. PMC: 7078228. DOI: 10.1038/s41421-020-0156-0. View